Bluejay Diagnostics, Inc. (BJDX) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Bluejay Diagnostics, Inc. is a clinical-stage medical diagnostics company developing the Symphony platform, a mobile device and single-use test cartridge system for rapid whole-blood testing in critical care settings. The company's primary focus is the Symphony IL-6 test for sepsis risk stratification. The company is currently in the development phase and has not yet received FDA clearance for its products.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(1,481,959) | $(2,297,998) | $(6,285,804) | $(7,651,146) |
| Operating Expenses | $1,361,607 | $2,341,233 | $5,684,972 | $7,924,493 |
| Cash and Equivalents (End of Period) | $5,755,741 (as of Sept 30, 2024) | |||
| Current Liabilities | $1,049,247 (as of Sept 30, 2024) | |||
| Accumulated Deficit | $(33,236,794) (as of Sept 30, 2024) | |||
| Net Cash Used in Operating Activities (YTD) | $(6,081,083) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately 42% in Q3 2024 compared to Q3 2023 ($1.36M vs. $2.34M). Research and Development (R&D) expenses dropped significantly from $1.4M to $0.55M, primarily due to reduced technology transfer efforts, partially offset by increased clinical trial costs.
- Interest Expense: The company incurred $190,610 in interest expense for Q3 2024, compared to zero in the prior year period, due to bridge note financing entered into in mid-2024.
- Capital Structure: The company completed a 1-for-8 reverse stock split on June 20, 2024. Additionally, significant equity financing occurred in Q1 and Q2 2024, including a public offering in June 2024 and bridge note financing, resulting in a substantial increase in cash balances from $2.2M at year-end 2023 to $5.8M at Q3 2024.
Outlook, Risks, and Management Commentary
- Going Concern Uncertainty: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. Current cash resources are projected to fund operations only through the first quarter of 2025. The company expects to need to raise additional capital within the next 12 months.
- Regulatory and Clinical Delays: The company initiated the SYMON-II pivotal clinical study in Q3 2024 but anticipates delays in FDA submission (beyond the next 18 months). These delays are attributed to technical challenges with the Symphony Cartridge product, including limited supply of critical components (e.g., antibodies) and reliability issues requiring validation.
- Nasdaq Compliance: The company is not in compliance with Nasdaq's minimum bid price requirement ($1.00). While a 1-for-8 reverse split was executed in June 2024, the stock price remained below the threshold. Nasdaq has granted an extension until February 24, 2025 to regain compliance. Shareholders have approved a potential further reverse split (ratios ranging from 1-for-20 to 1-for-50) to address this.
- Dilution Risk: Recent fundraising has resulted in significant ownership dilution. Future financing is likely to be highly dilutive given the company's market capitalization and cash burn rate.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise, as current funds are expected to last only until Q1 2025.
- Manufacturing Resolution: Monitor updates on the resolution of Symphony Cartridge supply chain and reliability issues, which are currently delaying the FDA submission.
- Nasdaq Status: Track the stock price relative to the $1.00 threshold and the board's decision on implementing the approved reverse stock split to avoid delisting.
- Warrant Overhang: Review the terms of the Class C and Class D warrants issued in June 2024, which represent a significant potential dilution (over 78 million shares combined) with low exercise prices.
- Bridge Note Repayment: Confirm the repayment status of the bridge notes issued in June 2024, which carry high interest costs.